Genfit AASLD KOL Event Nov 2018 in SF

San Francisco/Los Angeles, November 11, 2018

Expert speakers to discuss elafibranor including ongoing Phase 3 trial in NASH and Phase 2a trial in PBC

 

Expert KOL Speakers to Include:

Stephen A. Harrison, MD, FACP, FAASLD, COL(ret.), USA, MC
Visiting Professor of Hepatology, Radcliffe College of Medicine, University of Oxford
Medical Director, Pinnacle Clinical Research

Dr. Jörn M. Schattenberg
Universitätsmedizin Mainz, Germany

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Genfit SA [GNFTF] US$806 MM MCap
Lead pro­gram Ela­fi­branor is PPAR al­pha/del­ta ag­on­ist in Ph 3 for NASH with da­ta ex­pect­ed by YE 2019. An­nounced pos­i­tive ph 2 PBC da­ta in Dec 2018. An­nounced NASH bio­mark­er di­ag­nos­tic pro­gram; signed... [more in­for­ma­tion]